### Cervix

- **Therapeutic (Stage IB, IIA, IIB, IIIA, IIIB, IVA)**
  - *GOG-9926: A Phase I Evaluation Of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed By Paclitaxel And Carboplatin Chemotherapy In Women With Cervical Carcinoma Metastatic To The Para-Aortic Lymph Nodes To The Para-Aortic (Tewari)

- **Therapeutic (Stage IB1 & node positive, IB2, II, IIB, or IVA)**
  - *GOG-0274: Phase III trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients With Locally Advanced Cervical Cancer Stages IB2/IIB/IV A with Positive Lymph Nodes (Tewari)

- **Therapeutic (Stage IIIB-IV)**
  - **GOG 0265**: A Phase II Evaluation of Dalantercept (NSC# 992240, IND #101971) In Recurrent or Persistent Squamous Cell Carcinoma of the Cervix (Tewari)

- **Correlative**
  - *UCI 07-53: HPV L1 Gene Methylation as Biomarker of the progression of Cervical Neoplasia (Tewari)

- **EPI**
  - *UCI 12-47: Incidence of lymph node metastasis in women with early stage uterine cervical carcinoma with absence of lympho-vascular space invasion (Brueseke)(FS:Bristow)

- **EPI**
  - **GOG-0237**: Comparative Analysis Of CA 125, Human Papilloma Virus (HPV) In The Diagnosis Of Significant Cervical Lesions In Patients With A Cytologic Diagnosis Of Atypical Glandular Cells (AGC) (Tewari)

### Ovary

- **Therapeutic First Line Mucinous Epithelial (stage I recurrent or II-IV)**
  - *GOG-3001: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Women With Advanced Ovarian Cancer (Tewari)

- **Adjuvant (stage III-IV)**
  - **GOG-0212**: Randomized Phase III trial of maintenance Chemotherapy comparing 12 monthly cycles of single agent Paclitaxel of Xyotax (CT-2103) (IND #70177) versus no treatment until documented relapse in Women with advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancers (Tewari)

- **Secondary Adjuvant for Recurrent (Specific Hystology Types)**
  - **GOG-0213**: Phase III randomized controlled clinical trial of Carboplatin and Paclitaxel alone or in combination with Bevacizumab followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal, Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) (Tewari)

### For Info on Clinical Trials:

Call 1.877.UC.STUDY

Version 07.19.2013
**CURRENT OPEN* AND PENDING** **GYNECOLOGICAL CA TRIALS**

### Corpus Uteri / Endometrial

**Therapeutic Adjuvant for Advanced Stage (I-IVA)**

- *GOG-0258: Randomized Phase III trial of Cisplatin and Tumor Volume Directed Irradiation followed by Carboplatin and Paclitaxel versus Carboplatin and Paclitaxel for **optimally Debulked**, Advanced Endometrial Carcinoma (Tewari)

**Therapeutic First Line - Advanced Carcinosarcoma (Stage I-IV)**

- *GOG-0261: Randomized Phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naïve patients with newly diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus. (Tewari)

### Gynecologic CA

**Epidemiology**

- **EPI**: *UCI 11-32 Laparotomy, Laparoscopy and Robotic Surgery for the Treatment of Endometrial Cancer: a Cost-Effective Analysis (Moniaga) (FS:Bristow)
- **EPI**: *UCI 11-55 A Prospective Non-Randomized Comparison of Robotic Assisted Laparoscopic Radical Hysterectomy (RALRH) and Abdominal Radical Hysterectomy (ARH) (Tewari)
- **EPI**: *UCI 09-06 Long Term use of Bevacizumab in Women with Gynecologic Cancer (Randall)
- **EPI**: *GOG-0273 Chemotherapy toxicity in elderly women with ovarian, primary peritoneal, or fallopian tube cancer (Tewari)
- **EPI**: *UCI 12-46 Comparison of ovarian cancer surgical outcomes between referral and community hospitals (Brueseke) (FS:Bristow)
- **EPI**: **GOG 0235 A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy (Tewari)
- **EPI**: **UCI-13-27: Ovarian Cancer Patient-Centered Decision Aid (Wenzel)
- **EPI**: **UCI-13-29: The diagnostic performance of preoperative PET/CT to clarify local tumor factors in patients with early stage cervical cancer (Randall)
- **EPI**: **UCI 13-30 Short term morbidity and mortality associated with HIPEC in advanced ovarian carcinoma (Bristow)

### Correlative

- *UCI-13-09 Molecular Analysis of Alterations of the PI3K/AKT/mTOR Pathway in Lynch Syndrome-Associated Endometrial Cancer with Clinicopathologic Correlation (Tewari)
- *UCI 11-47 Molecular Profiling of Epithelial Ovarian Cancers to Predict Platinum Sensitivity and Resistance (Bristow)
- *UCI-11-20 OvaGene study of ovarian cancer biomarkers (Tewari)

### Other /Supportive Care

- *UCI 12-07 Impact of the PARO Therapeutic Robot on Quality of Life in Gynecologic Cancer patients Receiving Chemotherapy at an Outpatient